Health-related quality of life in small-cell lung cancer: A systematic review on reporting of methods and clinical issues in randomised controlled trials

The Lancet Oncology

Volumn 15, Issue 2, 2014, Pages

  Zikos, Efstathios ^a   Ghislain, Irina ^a   Coens, Corneel ^a   Ediebah, Divine E ^a   Sloan, Elizabeth ^b   Quinten, Chantal ^c   Koller, Michael ^d   van Meerbeeck, Jan P ^e   Flechtner, Hans Henning ^f   Stupp, Roger ^g   Pallis, Athanasios ^a   Czimbalmos, Agnes ^h   Sprangers, Mirjam A G ⁱ   Bottomley, Andrew ^a  

^a EORTC DATA CENTER   (Belgium)

^b NEW ENGLAND CENTER FOR CHILDREN   (United States)

^c EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^d UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^e ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^f OTTO VON GUERICKE UNIVERSITY   (Germany)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h Hungaroprax NC   (Hungary)

ⁱ UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MARIMASTAT; PLATINUM COMPLEX; VANDETANIB;

ANEMIA; BEFINDLICHKEITS SKALA 28 ITEM WELLBEING SCALE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; DAILY LIFE ACTIVITY; DIARRHEA; DRUG EFFICACY; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER CORE QUALITY OF LIFE QUESTIONNAIRE; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE 13 ITEM LUNG CANCER SPECIFIC QUETIONNAIRE; FATIGUE; HAIR LOSS; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; INFORMATION PROCESSING; LINEAR ANALOG SCALE ASSESSMENT; LOSS OF APPETITE; LUNG SMALL CELL CANCER; MONOTHERAPY; OUTCOME ASSESSMENT; PAIN; PRIORITY JOURNAL; PROFILE OF MOOD STATES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REVIEW; ROTTERDAM SYMPTOM CHECKLIST; SELF EVALUATION; SLEEP DISORDER; SYSTEMATIC REVIEW; VACCINATION; VISUAL ANALOG SCALE; WELLBEING;

ACTIVITIES OF DAILY LIVING; ADAPTATION, PSYCHOLOGICAL; COST OF ILLNESS; EVIDENCE-BASED MEDICINE; HUMANS; LUNG NEOPLASMS; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SMALL CELL LUNG CARCINOMA;

EID: 84892956730     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70493-5     Document Type: Review

References (67)

1. Johnson DH, Blot WJ, Carbone DP, et al. Cancer of the lung: non-small cell lung cancer and small cell lung cancer. Abeloff's Clinical Oncology 2008, 1307-1366. Elsevier Churchill Livingstone, Philadelphia, PA. 4th edn. M.D. Abeloff, J.O. Armitage, J.E. Niederhuber, M.B. Kastan, W.G. McKenna (Eds.).
2. Lally BE, Urbanic JJ, Blackstock AW, Miller AW, Perry MC Small cell lung cancer: have we made any progress over the last 25 years?. Oncologist 2007, 12:1096-1104.
3. Jackman DM, Johnson BE Small-cell lung cancer. Lancet 2005, 366:1385-1396.
4. Micke P, Faldum A, Metz T, et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer-what limits limited disease?. Lung Cancer 2002, 37:271-276.
5. Nasser HH, Lawrence HE Small-cell lung cancer: state of the art. Clin Lung Cancer 2002, 4:87-94.
6. van Meerbeeck JP, Fennell DA, De Ruysscher DK Small-cell lung cancer. Lancet 2011, 378:1741-1755.
7. Bottomley A, Flechtner H, Efficace F, et al. Health related quality of life outcomes in cancer clinical trials. Eur J Cancer 2005, 41:1697-1709.
8. Aaronson NK, Bullinger M, Ahmedzai S A modular approach to quality-of-life assessment in cancer clinical trials. Recent Results Cancer Res 1988, 111:231-249.
9. Bottomley A, Efficace F, Thomas R, Vanvoorden V, Ahmedzai S Health related quality of life in non-small-cell lung cancer: methodological issues in randomised controlled trials. J Clin Oncol 2003, 21:2989-2992.
10. Claassens L, van Meerbeeck J, Coens C, et al. Health-related quality of life (HRQOL) in non-small cell lung cancer (NSCLC): an update of a systematic review on methodological issues in randomized controlled trials (RCTs). J Clin Oncol 2011, 29:2104-2120.
11. Cochrane handbook for systematic reviews of interventions (version 5.1.0 updated March 2011) 2011, Cochrane Collaboration, Oxford. J.P.T. Higgins, S. Green (Eds.).
12. Efficace F, Bottomley A, Osoba D, et al. Beyond the development of health-related quality of life (HRQOL) measures: a checklist for evaluation of HRQOL outcomes in cancer clinical trials-does HRQOL evaluation in prostate cancer research inform clinical decision making?. J Clin Oncol 2003, 21:3502-3511.
13. Le Péchoux C, Dunant A, Senan S, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol 2009, 10:467-474. for the Prophylactic Cranial Irradiation (PCI) Collaborative Group.
14. Wolfson AH, Bae K, Komaki R, et al. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011, 81:77-84.
15. Le Péchoux C, Laplanche A, Faivre-Finn C, et al. Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). Ann Oncol 2011, 22:1154-1163. for the Prophylactic Cranial Irradiation (PCI) Collaborative Group.
16. Lee SM, Woll PJ, Rudd R, et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small-cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2009, 101:1049-1057.
17. Slotman BJ, Mauer ME, Bottomley A, et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. J Clin Oncol 2009, 27:78-84.
18. Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007, 357:664-672. for the EORTC Radiation Oncology Group and Lung Cancer Group.
19. Lee SM, James LE, Qian W, et al. Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small-cell lung cancer. Thorax 2009, 64:75-80.
20. Hermes A, Bergman B, Bremnes R, et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol 2008, 26:4261-4267.
21. Bottomley A, Debruyne C, Felip E, et al. Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer. Eur J Cancer 2008, 44:2178-2184.
22. Giaccone G, Debruyne C, Felip E, et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol 2005, 23:6854-6864.
23. Arnold AM, Seymour L, Smylie M, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007, 25:4278-4284. for the National Cancer Institute of Canada Clinical Trials Group Study BR.20.
24. O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006, 24:5441-5447.
25. Reck M, von Pawel J, Macha HN, et al. Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial. Lung Cancer 2006, 53:67-75.
26. Reck M, von Pawel J, Macha HN, et al. Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer. J Natl Cancer Inst 2003, 95:1118-1127.
27. Eckardt JR, von Pawel J, Papai Z, et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol 2006, 24:2044-2051.
28. Thatcher N, Qian W, Clark PI, et al. Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial. J Clin Oncol 2005, 23:8371-8379.
29. Sundstrøm S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002, 20:4665-4672. for the Norwegian Lung Cancer Study Group.
30. Shepherd FA, Giaccone G, Seymour L, et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002, 20:4434-4439.
31. Schiller JH, Adak S, Cella D, DeVore RF 3rd, Johnson DH. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593-a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 19: 2114-22.
32. Pujol JL, Daurès JP, Rivière A, et al. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst 2001, 93:300-308.
33. Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Stephens RJ Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. J Clin Oncol 2000, 18:395-404. Medical Research Council Lung Cancer Working Party.
34. Thatcher N, De Campos ES, Bell DR, et al. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer 1999, 80:396-402.
35. Gregor A, Cull A, Stephens RJ, et al. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. Eur J Cancer 1997, 33:1752-1758. for the United Kingdom Coordinating Committee for Cancer Research (UKCCCR), the European Organization for Research and Treatment of Cancer (EORTC)the European Organization for Research and Treatment of Cancer (EORTC).
36. Souhami RL, Spiro SG, Rudd RM, et al. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 1997, 89:577-580.
37. Bernhard J, Hürny C, Bacchi M, et al. Initial prognostic factors in small-cell lung cancer patients predicting quality of life during chemotherapy. Br J Cancer 1996, 74:1660-1667. for the Swiss Group for Clinical Cancer Research (SAKK).
38. Joss RA, Bacchi M, Hürny C, et al. Early versus late alternating chemotherapy in small-cell lung cancer. Ann Oncol 1995, 6:157-166. for the Swiss Group for Clinical Cancer Research (SAKK).
39. Hürny C, Bernhard J, Joss R, et al. "Fatigue and malaise" as a quality-of-life indicator in small-cell lung cancer patients. Support Care Cancer 1993, 1:316-320. for the Swiss Group for Clinical Cancer Research (SAKK).
40. Hürny C, Bernhard J, Joss R, et al. Feasibility of quality of life assessment in a randomized phase III trial of small cell lung cancer-a lesson from the real world. Ann Oncol 1992, 3:825-831. for the Swiss Group for Clinical Cancer Research SAKK.
41. James LE, Gower NH, Rudd RM, et al. A randomised trial of low-dose/high-frequency chemotherapy as palliative treatment of poor-prognosis small-cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 1996, 73:1563-1568.
42. Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Br J Cancer 1996, 73:406-413. Medical Research Council Lung Cancer Working Party.
43. Rowland KM, Loprinzi CL, Shaw EG, et al. Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol 1996, 14:135-141.
44. Gower NH, Rudd RM, Ruiz de Elvira MC, et al. Assessment of 'quality of life' using a daily diary card in a randomised trial of chemotherapy in small-cell lung cancer. Ann Oncol 1995, 6:575-580.
45. Souhami RL, Rudd R, Ruiz de Elvira MC, et al. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial. J Clin Oncol 12: 1806-13.
46. Ahles TA, Silberfarb PM, Rundle AC, et al. Quality of life in patients with limited small-cell carcinoma of the lung receiving chemotherapy with or without radiation therapy, for cancer and leukemia group B. Psychother Psychosom 1994, 62:193-199.
47. Perry MC, Eaton WL, Propert KJ, et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 1987, 316:912-918.
48. Bleehen NM, Girling DJ, Machin D, Stephens RJ A randomized trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC) I: survival and prognostic factors. Br J Cancer 1993, 68:1150-1156. Medical Research Council Lung Cancer Working Party.
49. Bleehen NM, Girling DJ, Machin D, Stephens RJ A randomized trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC) II: Quality of life. Br J Cancer 1993, 68:1157-1166. Medical Research Council Lung Cancer Working Party.
50. Anderson H, Hopwood P, Prendiville J, Radford JA, Thatcher N, Ashcroft L A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer. Br J Cancer 1993, 67:1385-1390.
51. Earl HM, Rudd RM, Spiro SG, et al. A randomised trial of planned versus as required chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 1991, 64:566-572.
52. Fayers PM, Bleehen NM, Girling DJ, Stephens RJ Assessment of quality of life in small-cell lung cancer using a Daily Diary Card developed by the Medical Research Council Lung Cancer Working Party. Br J Cancer 1991, 64:299-306.
53. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer: report to the Medical Research Council by its Lung Cancer Working Party. Br J Cancer 1989, 59:584-590. Medical Research Council Lung Cancer Working Party.
54. Wolf M, Pritsch M, Drings P, et al. Cyclic-alternating versus response-oriented chemotherapy in small-cell lung cancer: a German multicenter randomized trial of 321 patients. J Clin Oncol 1991, 9:614-624.
55. Blazeby JM, Avery K, Sprangers M, Pikhart H, Fayers P, Donovan J Health-related quality of life measurement in randomized clinical trials in surgical oncology. J Clin Oncol 2006, 24:3178-3186.
56. Schulz KF, Altman DG, Moher D CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Ann Intern Med 2010, 152:726-733. for the CONSORT Group.
57. Patient-reported outcomes (CONSORT PRO) CONSORT, (accessed Aug 7, 2013). http://www.consort-statement.org/extensions/data/pro.
58. Calvert M, Blazeby J, Revicki D, Moher D, Brundage M Reporting quality of life in clinical trials: a CONSORT extension. Lancet 2011, 378:1684-1685.
59. Calvert M, Blazeby J, Altman DG, et al. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 2013, 309:814-822.
60. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims US Department of Health and Human Services, Food and Drug AdministrationFood and Drug Administration, Center for Drug Evaluation and Research (CDER)Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER)Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH)Center for Devices and Radiological Health (CDRH), (accessed Aug 5, 2013). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf.
61. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP)Committee for Medicinal Products for Human Use (CHMP), (accessed Aug 5, 2013). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003637.pdf.
62. Hilbrich L, Sleight P Progress and problems for randomized clinical trials: from streptomycin to the era of megatrials. Eur Heart J 2006, 27:2158-2164.
63. Fehnel S, DeMuro C, McLeod L, Coon C, Gnanasakthy A US FDA patient-reported outcome guidance: great expectations and unintended consequences. Expert Rev Pharmacoecon Outcomes Res 2013, 13:441-446.
64. Efficace F, Bottomley A, Vanvoorden V, Blazeby JM Methodological issues in assessing health-related quality of life of colorectal cancer patients in randomised controlled trials. Eur J Cancer 2004, 40:187-197.
65. Efficace F, Bottomley A, van Andel G Health related quality of life in prostate carcinoma patients: a systematic review of randomized controlled trials. Cancer 2003, 97:377-388.
66. Efficace F, Bottomley A Health related quality of life assessment methods and reported outcomes in randomised controlled trials of primary brain cancer patients. Eur J Cancer 2002, 38:1824-1831.
67. Brundage M, Bass B, Davidson J, et al. Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers. Qual Life Res 2011, 20:653-664.